Document is current
Any future updates will be listed below
-
Authors
Shneyderman, Anastasia https://orcid.org/0000-0002-1155-2551
Hammer, Sandra S. https://orcid.org/0009-0003-7760-4582
Remmel, H. Lawrence https://orcid.org/0000-0002-5742-829X
Veviorskiy, Alexander https://orcid.org/0009-0009-1006-5944
Alawi, Khadija M. https://orcid.org/0000-0002-9208-9131
Ustiugova, Alina https://orcid.org/0000-0002-1065-4206
Korzinkin, Mikhail https://orcid.org/0009-0002-1866-4318
Zhavoronkov, Alex https://orcid.org/0000-0001-7067-8966
Quay, Steven C. https://orcid.org/0000-0002-0363-7651
- License Information
-
More Information
Article History
Received: 9 May 2025
Accepted: 25 September 2025
First Online: 31 October 2025
Competing interests
: Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development and engaged in aging and cancer research. AS, AV, KMA, AU, MK, AZ are affiliated with Insilico Medicine. SQ, HLR, and SSH each hold shares in Atossa Therapeutics, Inc. but declare no non-financial competing interests. HLR is lead independent director of Atossa Therapeutics, Inc.
